Important Contract and £10m placing for Angle (AIM:AGL)
There were two important announcements from Angle today (25 May). Firstly there was news that the Company has signed a contract with the University of Manchester, acting through the Cancer Research UK Manchester Institute, which will allow the incorporation of Angle’s Parsortix system for routine use in clinical trials and for research purposes. In a separate announcement, Angle reported that it had completed a placing with institutional investors to raise £10.2 million.
Angle (AIM: AGL) http://www.angleplc.com/ Introduction Angle is a specialist Medtech Company focused on commercialising its patented Parsortix liquid biopsy system. The Company believes that Parsortix has the potential to transform the diagnosis and treatment of cancer by making it possible to harvest intact cancer cells from a patient’s blood for analysis. Investor’s Champion has reported on progress with Angle on a number of previous occasions - previous articles can be found using the Search facility at the top of this page. Research Revenue Over the years much work has been undertaken to develop, prove and promote Parsortix to potential customers…